| Objective First part:to further study the Indole-3-carbinol on the prevention of breast cancer in rats and the inhibition of ER receptor expression in mammary tumors. Sencond part: to further study the Indole-3-carbinol on the treatment of mammary gland hyperplasia in rats. Methods First part:(1) 43 days old 40 Wistar rats were randomly divided into the model groups (only DMBA gavage), high-dose group (I3C, 100 mg / d), low-dose group (I3C, 50 mg / d), the control group( n = 10). High-dose group and low-dose group were given Indole-3-carbinol a week before the model group for prevention. After that, the model group, the high-dose group and low-dose group were given DMBA 30mg/ml at one time 1ml per one rats, then the high-dose group and low-dose group were given Indole-3-carbinol 100 mg / d and 50 mg / d to the end of the experiment (total of 100 days) respectively. The incidence of mammary tumors was observed, the number of tumors was recorded and the volumes were measured. The histological structures were observed under the light microscopy and the tumors were classified by pathological standard. (2) ER alpha and ER beta expression was observed in each mammary tumor of each group by S-P immunohistochemical method.Second part: (1) 43 days old 30 Wistar rats were randomly divided into the model groups, drug treatment group (I3C, 100 mg / d), and the control group (n = 10). Drug treatment group and the control group at the same time were modeled: 20 rats were given lower extremities intramuscular estradiol benzoate 0.5 mg/kg, 1ml/days, a series of injection 20 days; and then sequential injection progesterone, 5mg/kg, 1ml/day, for 5 days; hyperplasia model after the success of 20 rats given indole-3-carbinol solution 100mg/ ml (dissolved in 0.5% methylcellulose solution made from hanging turbid liquid) 1ml per day gavage 30 days; and the control group was given the solvent methyl cellulose solution gavage to the end of the experiment. During the experiment, the process of rat papillary breast size and colour change were observed and recorded; and then observed under light microscope to classify the breast hyperplasia degree in pathology; the second and third nipple height were measured and recorded by electronic vernier caliper; and reproductive six is inspected (E2, FSH, PRL, PROG, TSTO, LH) by radioimmunary method. Results First part:(1) The average increased weight in each group contrast:the average weight of each group for the beginning of the experiment is135.11±9.91g.Weight of high-dose treatment group is 142.77±4.26g; increased average weight of low-dose treatment group is146.8±5.57g; increased weight of the model group is126.44±5.35g; increased weight of solvent control group is 158.74±6.67g.,P = 0.000 <0.001, the difference is obvious statistical significance. (2) The number of rat mammary tumor and the average size of tumor volumes (x±s): the number of rats bearing the tumor was 3 in high-dose group, and 3 in low-dose were more statistically significant differences (p <0.05) than 9 in the model group; the number of tumors was 7 in high-dose group, 13 in low-dose group, and 21 in the model group, respectively. And the average tumor size was 827.62±497.19 mm3 in high-dose group , 2258.46±374.27 mm3 in low-dose group compared to 3086.08±462.86 mm3 in model group was also significantly different (p <0.05); but those in the high-dose group and low-dose group were no statistical difference (p> 0.05).Second part: (1) The average increased weight in each group contrast: average weight of drug treatment group is 120.51±4.99g; average increased weight of the model group is 134±5.65g; solvent control is123.24±1.67g; P = 0.000 < 0.001, the difference is obvious statistical significance.(2) At the end of the experimental nipple high of rats were compared (x±s): in model group, measurement of nipple height of rats (2,3 right) were 2.18±0.10mm and 2.21±0.08mm, and in contrast, in drug treatment group measurement of rats nipple height (2,3 right) were 1.68±0.0mm, 1.71±0.04mm, which is lower than the model group, and the difference was also statistical significance(P<0.01). (3) Histological light microscopy observation: in the drug treatment group, the number of severe breast hyperplasia is six (30%); and in the modle group the number is sixteen (80%), the difference has statistically significant (P<0.01); but in drug treatment group, the number of no breast hyperplasia is six (30%), which was significantly more than the number of the model group, which has zero (0%) of no breast model hyperplasia (P<0.01); and in drug treatment group, the number of mild breast hyperplasia are eight (40%) compared to four (20%) of the model group, and the difference was no statistically significant (P>0.05). (4) At the end of the experimental the measurement of six reproductive of rats were compared (x±s): FSH: FSH of the drug treatment group in rats is 1.01±0.16 mIu / ml, compared to the model group 17.76±0.25 mIu / ml, the difference was obvious statistical significance (P <0.05); E2: E2 of the drug treatment group in rats is 34.54±5.32 ng / ml, which is lower than the model group 50.59±3.03 ng / ml, and the difference was obvious statistical significance (P<0.05); PRL: PRL of the model group in rats are 93.52±9.67 uIu / ml, compared to 54.14±7.21 uIu / ml of the drug treatment group, and the difference was obvious statistical significance (P< 0.01); so in above the drug treatment group compared to the model group, the level of these three indicators has declined markedly. And PROG: PROG of drug treatment group is 23.06±4.21 ng/ml, which is higher than 8.43±3.93 ng / ml in the model group, and the difference was statistically significant( P<0.05); TSTO: TSTO of Drug treatment group is 0.31±0.04 ng / ml ,which is higher than 0.19±0.01 ng/ml of the model group, and the difference was statistically significance (P = <0.05); in drug treatment group, LH in the blood is 8.74±0.40 ng / ml ,which is also higer than LH of the model group 6.48±0.71 ng / ml, and the difference was statistically significance (P<0.05); then in above three indicators, those in the drug treatment group were higher than the control group. Conclusion First part:indole-3-carbinol has the significant effects on the inhibition of breast cancer as the result, but high-dose and low-dose have no difference; and it can effectively block ER receptor expression of tumors, then the expression can be reduced.Second part: indole-3-carbinol can reduce the height of breast nipple in mammary gland hyperplasia of rats; and has some therapeutic effects on the rat mammary gland hyperplasia, especially in the severe breast hyperplasia; and can significantly decreased the FSH, E2 and PRL levels in rats blood. |
PDF Full Text Request